In a network meta-analysis of 25 randomized trials, sonelokimab was ranked highest for treating patients with moderate-to-severe hidradenitis suppurativa (HS). Adalimumab, lutikizumab, and bimekizumab ...
Correspondence to Dr Ada Tang, School of Rehabilitation Sciences, McMaster University Faculty of Health Sciences, Hamilton, Canada; atang{at}mcmaster.ca Objective To determine the superiority of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback